Thus, TXNIP may serve as a new therapeutic target for the treatment of Reye-like syndrome, and deficiency in TXNIP may be associated with the mechanism of fatty liver caused by other clinical conditions, such as ALD or NAFLD, or drug-induced fatty liver. Here, TXNIP is linked to fatty liver disease.